Patrys Limited · ASX:PAB
Patrys — AusBiotech Life Sciences Investment Summit 2009
7 slides from Patrys's conference presentation, Oct 27, 2009
Slide 1: Natural Human Antibodies to Treat Human Diseases
Natural Human Antibodies to Treat Human Diseases For personal use only Patrys is the only company in the world that can systematically develop natural human antibody- based therapies for the treatment of cancer AusBiotech Life Sciences Natural human Investment Summit Presentation October 2009 antibo
Slide 2: Overview
Overview For personal use only Strong positioning in high demand market Antibody sales remain strong (expected US$50B in 2011); antibody deal values increased in 2009 Patrys products offer therapeutic advantages; protected by broad intellectual property “Portfolio” of multiple commercial opportuniti
Slide 3: Natural Antibody Immunity to Cancer
Natural Antibody Immunity to Cancer For personal use only All humans generate cancer Antibody production compromised cells b/c of age, illness, genetic weaknesses Human immune system, including antibodies, prevents full blown cancer in >99.8% of Cancer grows abnormally fast due to general population
Slide 4: Product/Competitive Advantages
Product/Competitive Advantages For personal use only Patrys’ Natural Human Antibodies vs. Marketed Factor Antibodies/Chemo/Radiation Attack only diseased tissue; marketed antibodies also attack healthy tissues Safer Evoke less reaction from patient’s immune system because natural Effectively coordin
Slide 5: Lead Product Pipeline and Milestones
Lead Product Pipeline and Milestones For personal use only PAT-SC1 2009: acquired clinical product 2010: Scale-up manufacturing 2011: Broaden clinical trials PAT-LM1 and PAT-SM6 2009: Completed preclinical develop 2009: Completed scale up production 2009: PAT-SM6 human clinical trial 2010: PAT-LM1 h
Slide 6: Value Proposition
Value Proposition For personal use only Patrys Share Price (ASX:PAB) Recent advances only partially reflected in value (currently 24% of pre-GFC level) Trading volume in Sep ‘09 > 5X volume in March ‘09 ‘07 to ‘09 Antibody Deal Values Major milestones to come as Patrys becomes clinical stage company
Slide 7: Summary
Summary For personal use only Strong positioning in high demand market “Portfolio” of commercial opportunities Increased financial strength and asset values in challenging times Significant upcoming commercial milestones in a rebounding industry 7
Patrys — AusBiotech Life Sciences Investment Summit 2009 on 6ix